Cargando…
Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
Multiple sclerosis (MS) is the most common autoimmune illness of the central nervous system. For many years the inflammatory manifestations of MS were treated using only corticosteroids. Since the 1990s the results of several clinical trials with immunomodulatory agents have changed the therapeutic...
Autores principales: | Paolicelli, Damiano, Direnzo, Vita, Trojano, Maria |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726074/ https://www.ncbi.nlm.nih.gov/pubmed/19707422 |
Ejemplares similares
-
The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy
por: Paolicelli, Damiano, et al.
Publicado: (2016) -
Gender differences in safety issues during Fingolimod therapy: Evidence from a real‐life Relapsing Multiple Sclerosis cohort
por: Manni, Alessia, et al.
Publicado: (2017) -
A case report of late‐onset atypical Hemolytic Uremic Syndrome during interferon beta in multiple sclerosis: Open issues in literature review
por: Parisi, Mosè, et al.
Publicado: (2020) -
Impact of Natalizumab on Cognitive Performances and Fatigue in Relapsing Multiple Sclerosis: A Prospective, Open-Label, Two Years Observational Study
por: Iaffaldano, Pietro, et al.
Publicado: (2012) -
Low Serum Urate Levels Are Associated to Female Gender in Multiple Sclerosis Patients
por: Zoccolella, Stefano, et al.
Publicado: (2012)